RT Journal Article
T1 Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Withdrawal Is Associated with Higher Mortality in Hospitalized Patients with COVID-19.
A1 Roy-Vallejo, Emilia
A1 Sanchez-Purificacion, Aquilino
A1 Torres-Peña, Jose David
A1 Sanchez-Moreno, Beatriz
A1 Arnalich, Francisco
A1 Garcia-Blanco, Maria Jose
A1 Lopez-Miranda, Jose
A1 Romero-Cabrera, Juan Luis
A1 Herrero-Gil, Carmen Rosario
A1 Bascunana, Jose
A1 Rubio-Rivas, Manuel
A1 Pintos-Otero, Sara
A1 Martinez-Sempere, Veronica
A1 Ballano-Rodriguez-Solis, Jesus
A1 Gil-Sanchez, Ricardo
A1 Luque-Del-Pino, Jairo
A1 Gonzalez-Noya, Amara
A1 Navas-Alcantara, Maria Sierra
A1 Cortes-Rodriguez, Begoña
A1 Alcala, Jose Nicolas
A1 Suarez-Lombraña, Ana
A1 Andres-Soler, Jorge
A1 Gómez-Huelgas, Ricardo
A1 Casas-Rojo, Jose Manuel
A1 Millan-Nuñez-Cortes, Jesus
K1 ACEI
K1 ARB
K1 COVID-19
K1 MACE
K1 Prognosis
K1 Área Sanitaria Norte de Córdoba
K1 Area de Gestión Sanitaria Sur de Córdoba
AB Our main aim was to describe the effect on the severity of ACEI (angiotensin-converting enzyme inhibitor) and ARB (angiotensin II receptor blocker) during COVID-19 hospitalization. A retrospective, observational, multicenter study evaluating hospitalized patients with COVID-19 treated with ACEI/ARB. The primary endpoint was the incidence of the composite outcome of prognosis (IMV (invasive mechanical ventilation), NIMV (non-invasive mechanical ventilation), ICU admission (intensive care unit), and/or all-cause mortality). We evaluated both outcomes in patients whose treatment with ACEI/ARB was continued or withdrawn. Between February and June 2020, 11,205 patients were included, mean age 67 years (SD = 16.3) and 43.1% female; 2162 patients received ACEI/ARB treatment. ACEI/ARB treatment showed lower all-cause mortality (p < 0.0001). Hypertensive patients in the ACEI/ARB group had better results in IMV, ICU admission, and the composite outcome of prognosis (p < 0.0001 for all). No differences were found in the incidence of major adverse cardiovascular events. Patients previously treated with ACEI/ARB continuing treatment during hospitalization had a lower incidence of the composite outcome of prognosis than those whose treatment was withdrawn (RR 0.67, 95%CI 0.63–0.76). ARB was associated with better survival than ACEI (HR 0.77, 95%CI 0.62–0.96). ACEI/ARB treatment during COVID-19 hospitalization was associated with protection on mortality. The benefits were greater in hypertensive, those who continued treatment, and those taking ARB.
PB MDPI AG
SN 2077-0383
YR 2021
FD 2021-06-11
LK http://hdl.handle.net/10668/18098
UL http://hdl.handle.net/10668/18098
LA en
NO Roy-Vallejo E, Sánchez Purificación A, Torres Peña JD, Sánchez Moreno B, Arnalich F, García Blanco MJ, et al. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Withdrawal Is Associated with Higher Mortality in Hospitalized Patients with COVID-19. J Clin Med. 2021 Jun 15;10(12):2642.
DS RISalud
RD Sep 21, 2025